18F-fluoromisonidazole PET reveals spatial and temporal heterogeneity of hypoxia in mouse models of human non-small-cell lung cancer

Future Oncology

Volumn 11, Issue 20, 2015, Pages 2841-2849

  Cui, Ya Li ^a   Wang, Xuemei ^b   Li, Xiao Feng ^c  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Inner Mongolia Medical University affiliated Hospital   (China)

^c University of Louisville School of Medicine   (United States)

Author keywords

18F fluoromisonidazole; change in hypoxia; hypoxia; non small cell lung cancer; tumor microenvironment

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; CARBONATE DEHYDRATASE IX; PIMONIDAZOLE; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; MISONIDAZOLE; RADIOPHARMACEUTICAL AGENT;

A549 CELL LINE; ANIMAL CELL; ARTICLE; AUTORADIOGRAPHY; DIGITAL AUTORADIOGRAPHY; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; HYPOXIC CELL; IMMUNOHISTOCHEMISTRY; MICROSCOPY; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANOXIA; CELL HYPOXIA; DISEASE MODEL; IMAGE PROCESSING; LUNG TUMOR; NUDE MOUSE; PROCEDURES; SCINTISCANNING; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANOXIA; AUTORADIOGRAPHY; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HETEROGRAFTS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICE; MICE, NUDE; MISONIDAZOLE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84944731630     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.205     Document Type: Article

References (34)

1. Huff CA, Matsui W, Smith BD, Jones RJ. The paradox of response and survival in cancer therapeutics. Blood 107, 431-434 (2006).
2. Thomlinson R, Gray L. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer 9, 539-549 (1955).
3. Rockwell S, Dobrucki IT, Kim EY, Marrison ST, Vu VT. Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr. Mol. Med. 9, 442-458 (2009).
4. Höckel M, Schlenger K, Aral B et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56, 4509-4515 (1996).
5. Brizel DM, Sibley SG, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 38, 285-289 (1997).
6. Goethals L, Debucquoy A, Perneel C et al. Hypoxia in human colorectal adenocarcinoma: comparison between extrinsic and potential intrinsic hypoxia markers. Int. J. Radiat. Oncol. Biol. Phys. 65, 246-254 (2006).
7. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 41, 31-39 (1996).
8. Wouters BG, Weppler SA, Koritzinsky M et al. Hypoxia as a target for combined modality treatments. Eur. J. Cancer 38, 240-257 (2002).
9. Höckel M, Knoop C, Schlenger K, Vorndran B, Knapstein PG, Vaupel P. Intratumoral pO2 histography as predictive assay in advanced cancer of the uterine cervix. Adv. Exp. Med. Biol. 345, 445-450 (1994).
10. Ljungkvist AS, Bussink J, Kaanders JH et al. Hypoxic cell turnover in different solid tumor lines. Int. J. Radiat. Oncol. Biol. Phys. 62, 1157-1168 (2005).
11. Ljungkvist AS, Bussink J, Kaanders JH, van der Kogel AJ. Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers. Radiat. Res. 167, 127-145 (2007).
12. Huang T, Civelek AC, Li J et al. Tumor microenvironment-dependent 18F-FDG, 18F-fluorothymidine, and 18F-misonidazole uptake: a pilot study in mouse models of human non-small cell lung cancer. J. Nucl. Med. 53, 1262-1268 (2012).
13. Gifford GE. Some effects of anaerobiosis on the growth and metabolism of HeLa cells. Exp. Cell Res. 31, 113-118 (1962).
14. Littbrand B, Revesz L. Survival of cells in anoxia. Br. J. Radiol. 41, 479-480 (1968).
15. Koch CJ, Kruuv J, Frey HE. The effect of hypoxia on the generation time of mammalian cells. Radiat. Res. 53, 43-48 (1973).
16. Koch CJ, Kruuv J, Frey HE et al. Plateau phase in growth induced by hypoxia. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 23, 67-74 (1973).
17. Wang Z, Li G, Liu S, Cui Y-L. 99mTc-HL91 detecting hypoxia in lung cancer and its effect on radiotherapy management. Chin. J. Gerontol. 30, 30-31 (2013).
18. Rajendran JG, Krohn KA. F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapy. Semin. Nucl. Med. 45, 151-162 (2015).
19. Yasuda K, Onimaru R, Okamoto S et al. [18F] fluoromisonidazole and a new PET system with semiconductor detectors and a depth of interaction system for intensity modulated radiation therapy for nasopharyngeal cancer. Int. J. Radiat. Oncol. Biol. Phys. 85, 142-147 (2013).
20. Carlin S, Zhang H, Reese M, Ramos NN, Chen Q, Ricketts SA. A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers. J. Nucl. Med. 55, 515-521 (2014).
21. Troost EG, Laverman P, Philippens ME et al. Correlation of [18F] FMISO autoradiography and pimonidazole immunohistochemistry in human head and neck carcinoma xenografts. Eur. J. Nucl. Med. Mol. Imaging 35, 1803-1811 (2008).
22. Li XF, Ma Y, Sun X, Humm JL, Ling CC, O'Donoghue JA. High 18F-fluorodeoxyglucose (18F-FDG) uptake in microscopic peritoneal tumors requires physiological hypoxia. J. Nucl. Med. 51, 632-638 (2010).
23. O'Donoghue JA, Zanzonico P, Pugachev A et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int. J. Radiat. Oncol. Biol. Phys. 61, 1493-1502 (2005).
24. Li XF, Sun X, Ma Y et al. Detection of hypoxia in microscopic tumors using 131I-labeled iodo-azomycin galactopyranoside (131I-IAZGP) digital autoradiography. Eur. J. Nucl. Med. Mol. Imaging 37, 339-348 (2010).
25. Zhang G, Li J, Wang X et al. The reverse Warburg effect and 18F-FDG uptake in non-small cell lung cancer A549 in mice: a pilot study. J. Nucl. Med. 56(4), 607-612 (2015).
26. Huang T, Civelek AC, Zheng H et al. (18) F-misonidazole PET imaging of hypoxia in micrometastases and macroscopic xenografts of human non-small cell lung cancer: a correlation with autoradiography and histological findings. Am. J. Nucl. Med. Mol. Imaging 3(2), 142-153 (2013).
27. Li J, Zhang G, Wang X, Li XF. Is carbonic anhydrase IX a validated target for molecular imaging of cancer and hypoxia? Future Oncol. 11(10), 1531-1541 (2015).
28. Li XF, Carlin S, Urano M, Russell J, Ling CC, O'Donoghue JA. Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy. Cancer Res. 67(16), 7646-7653 (2007).
29. Li XF, Huang T, Jiang H et al. Combined injection of 18F-fluorodeoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine PET achieves more complete identification of viable lung cancer cells in mice and patients than individual radiopharmaceutical: a proof-of-concept study. Transl. Oncol. 6(6), 775-783 (2013).
30. Graves EE, Maity A, Le QT. The tumor microenvironment in non-small cell lung cancer. Semin. Radiat. Oncol. 20, 156-163 (2010).
31. Sachpekidis C, Thieke C, Askoxylakis V, Nicolay NH, Huber PE, Thomas M et al. Combined use of 18F-FDG and 18F-FMISO in unresectable non-small cell lung cancer patients planned for radiotherapy: a dynamic PET/CT study. Am. J. Nucl. Med. Mol. Imaging 5(2), 127-142 (2015).
32. Nehmeh SA, Lee NY, Schröder H et al. Reproducibility of intratumor distribution of 18F-fluoromisonidazole in head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 70, 235-242 (2008).
33. Okamoto S, Shiga T, Yasuda K et al. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer. J. Nucl. Med. 54, 201-207 (2013).
34. Sun X, Li XF, Russell J et al. Changes in tumor hypoxia induced by mild temperature hyperthermia as assessed by dual-tracer immunohistochemistry. Radiother. Oncol. 88(2), 269-276 (2008).